Research
The human microbiota, including the microbes living on/in the human body, modulates host biology in multiple ways. My research aims to study the chemistry and biology behind microbe-host interactions in the context of health and disease at the level of molecular mechanisms. My long-term goal is to understand and reprogram the molecular "language" of host-microbe interactions for potential therapeutic applications. Using a combination of bioinformatics, microbial genetics, metabolomics, chemical biology, and pre-clinical mouse models, our lab focus on three principles that are changing our understanding of how the human microbiota impact health and disease:
I. New genetic tools for the human microbiota. We have developed the first CRISPR-Cas9 based genetic system for a Clostridium commensal Clostridium sporogenes. We are interested in applying the CRISPR-Cas9 technology to other gut bacteria that have shown a strong correlation with human health and disease but are currently not genetically tractable.
II. Modulating microbiota small molecules in the host and study their effects on host biology. An increasing number of studies are revealing important connections between microbiome-derived metabolites and human diseases like inflammatory bowel disease and colon cancer. We will focus on a group of molecules that are derived via microbial fermentation of nutrients (e.g. propionate and butyrate). These molecules are highly abundant and circulatory (have body-wide effects) in the body and their levels can be manipulated via genetic engineering of the gut microbiome. We will apply the genetic tools in the lab to toggle on/off these microbiota metabolites in vivo and investigate their effects on host intestinal immunity and IBD development.
III. Regulating the metabolic interaction between host and gut microbiota. The microbiome is one of the key orchestrators in mediating human health. We will use bioinformatics and molecular genetics to design and engineer a microbiota community for a predefined function in regulating host intestinal immunity for IBD treatment.
Bio
Chun-Jun (CJ) Guo is an Assistant Professor in the Jill Roberts Institute for Research in Inflammatory Bowel Disease, Department of Medicine at Weill Cornell Medicine. He received his B.Sc. in Pharmacy from the School of Pharmacy, Fudan University, China in 2009, and his Ph.D. from the School of Pharmacy, the University of Southern California in 2015, where he studied fungal secondary metabolism in Dr. Clay Wang’s group. As a postdoctoral fellow, he worked with Dr. Michael Fischbach at Stanford University where he studied small molecules produced by the human microbiota. Started in 2018, his lab at Weill Cornell Medicine aims to develop new tools to genetically manipulate the human microbiota and investigate the molecular mechanisms behind microbiome-host physiology interaction.
Distinctions.
- 2023 The Scialog Award
- 2022 Kenneth Rainin Foundation Innovator Award
- 2020 The Noster & Science Microbiome Runner-Up Prize
- 2020 AGA-Allergan Foundation Pilot Research Award in IBD
- 2019 NIH Director’s New Innovator Award